

PII: S0040-4039(96)01310-X

SYNTHESIS OF THE ANTIFOULING POLYAMINE PSEUDOCERATIDINE AND ITS ANALOGS: FACTORS INFLUENCING BIOCIDAL ACTIVITY

James A. Ponasik, Darren J. Kassab, and Bruce Ganem*

Department of Chemistry, Baker Laboratory Cornell University, Ithaca, NY 14853-1301 USA

Abstract: Syntheses of the title compound 1 and its N⁸ and N¹-monoacylated analogs 5 and 8, respectively, are reported. Assays of 1, 5, and 8 indicate that the number and position of the acyl substituents affect bioactivity. Copyright © 1996 Elsevier Science Ltd

The development of effective, low-cost biocides that are compatible with marine coatings has had a major impact on both the recreational and commercial maritime industries, with worldwide demand for such paints now approaching \$2 billion.¹ By preventing barnacles, mollusks, and other organisms from becoming attached to ships' hulls, antifouling agents can block corrosion and significantly improve fuel efficiency. Tributyltin-based compounds, which can be formulated as co-polymers using tributyltin methacrylate, have been the most widely used antifoulants. However, recent concern about their effects on marine mammals² and other organisms³ has led to a ban on the use of tributyltin-containing coatings in the United States, Japan, and other countries. Thus we were intrigued by the report that pseudoceratidine 1, a derivative of the polyamine spermidine isolated from the marine sponge *Pseudoceratine purpurea*, showed promising properties as an antifouling compound.⁴

Although widely distributed throughout the plant and animal kingdoms,⁵ relatively few polyamines are known of marine origin.⁶⁻⁸ Many of these substances exhibit antimicrobial, cytotoxic, or antifungal activity. Here we report the synthesis of 1 and its N⁸ and N¹-monoacylated congeners 5 and 8, together with additional bioassays that help identify the structural requirements for bioactivity.

Pseudoceratidine is likely biosynthesized from spermidine and 4,5-dibromo-2-pyrrolic acid 2, a known immunosuppressive agent that was first isolated from deep-water marine sponges.⁹ Published syntheses of acid 2 involve bromination of methyl 2-pyrrolecarboxylate with subsequent deesterification.¹⁰ However, we found that compound 2 (mp 148 °C) was more conveniently prepared in nearly quantitative yield by the direct bromination of pyrrole-2-carboxylic acid.¹¹ Conversion of 2 to the corresponding acylimidazole and *in situ* coupling of 3 (2 equiv) with spermidine by the method of Joshua and Scott¹² gave 1 in 73% yield after chromatography (SiO₂, 75:25:3 CH₂Cl₂:CH₃OH:NH₄OH). Spectral data on synthetic 1 matched published values for the natural product.

Br
$$NH_2$$
 NH_2 NH_2

We have previously used adduct 4 of spermidine and formaldehyde 13 to prepare N^1 and N^8 -acetyl-spermidines. 14 A variation of that approach, shown below, afforded the corresponding monoacyl analogs of 1.

To synthesize N⁸-(dibromopyrroloyl)-spermidine 5, the primary amine in 4 was selectively acylated with 3, then the hexahydropyrimidine protecting group was removed in a Knoevenagel condensation with ethyl

hydrogen malonate. The overall yield of 5 from 4 was 68%.¹⁵ To prepare N¹-(dibromopyrroloyl)-spermidine 8, triamine 4 was first transformed to its N⁸-BOC-derivative 6, then deprotected to afford N⁸-BOC-spermidine 7.¹⁶,¹⁷ Acylation of 7 with 3 followed by acid treatment gave 8 in 30% yield from 6.¹⁸

Pseudoceratidine was reported to inhibit metamorphosis of the barnacle *Balanus amphitrite* (ED₅₀ = 8 μ g/mL),⁴ suggesting a potential effect on chitinase; however, no inhibition of *Streptomyces griseus* chitinase was observed. Compounds 1, 5, and 8 were also assayed against a variety of other microorganisms (see Table). While both 5 and 8 were less active than pseudoceratidine, isomer 5 was significantly more potent than 8 against *Staphylococcus aureus* and *Escherichia coli*. Discrimination of the two ends of the polyamine chain appeared to play a significant role in biological activity.

Compound Antibiotic Activity (Minimum Inhibitory Concentration; values in µg/mL)

	S. aureus	E. coli	P. aeruginosa	C. albicans
1	4	32	128	32
5	64	128	256	128
8	>256	256	>256	>256

ACKNOWLEDGMENT: We thank the National Institutes of Health for financial assistance (Program Project Grant GM 44874 on structure-based drug design). We are also grateful to Dr. William E. Kinney of Magainin Pharmaceuticals Inc. (Plymouth Meeting, PA) for biological assays on 1, 5, and 8, and to Dr. Franklin M. Loew (College of Veterinary Medicine, Cornell University) for valuable discussions. Generous financial support of the Cornell NMR Facility has been provided by the NSF (CHE 7904825; PGM 8018643) and NIH (RR02002).

REFERENCES AND NOTES

- 1. Layman, P. L. Chemical and Engineering News 1995, (May 1), 23.
- 2. Iwata, H.; Tanabe, S.; Mizuno, T.; Tatsukawa, R. Environ. Sci. Tech. 1995, 29, 2959.
- 3. Ohhira, S.; Matsui, H.; Nitta, K. Vet. Human Toxicol. 1996, 38, 206.
- 4. Tsukamoto, S.; Kato, H.; Hirota, H.; Fusetani, N. Tetrahedron Lett. 1996, 37, 1439.
- 5. Tabor, C. W.; Tabor, H. Ann. Rev. Biochem. 1976, 45, 285.
- Simple alkyl and/or acylspermidines: (a) Schmitz, F. J.; Hollenbeak, K. H.; Prasad, R. S. Tetrahedron
 Lett. 1979, 3387; (b) Kazlauskas, R.; Murphy, P. T.; Ravi, B. N.; Sanders, R. L.; Wells, R. J. Aust. J.
 Chem. 1982, 35, 69.

- 7 Crambescidin and ptilomycalin guanidine alkaloids: (a) Jares-Erijman, E. A.; Sakai, R.; Rinehart, K. L. J. Org. Chem. 1991, 56, 5712; (b) Kashman, Y.; Hirsh, S.; McConnell, O. J.; Ohtini, I.; Kusumi, T.; Kakisawa, H. J. Am. Chem. Soc. 1989, 111, 892.
- Squalamine, a steroidal polyamine: (a) Moore, K. S.; Wehrli, S.; Roder, H.; Rogers, M.; Forrest, J. N.;
 McCrimmon, D.; Zasloff, M. Proc. Natl. Acad. Sci. USA 1993, 90, 1354; (b) Wehrli, S. L.; Moore, K.
 S.; Roder, H.; Durell, S.; Zasloff, M. Steroids 1993, 58, 370.
- (a) Gunasekera, S. P.; Cranick, S.; Longley, R. E. J. Nat. Prod. 1989, 52, 757; (b) see also Nanteuil,
 G.; Ahond, A.; Poupat, C.; Thoison, O.; Potier, P. Bull. Soc. Chim. Fr. 1986, 813.
- (a) Anderson, H. J.; Lee, S.-F. Can J. Chem. 1965, 43, 409; (b) Hodge, P.; Rickards, R. W. J. Chem. Soc. 1965, 459.
- 11. Bromine (9.2 mmol) in HOAc (6.2 mL) was added to 2 (4.6 mmol) in HOAc (25 mL). The solution was heated to 60 °C for 1 h, then decolorized (Norit) and concentrated *in vacuo*. Recrystallization from H₂O:EtOH gave 2 (1.17 g, 94%): mp 170 °C (d); lit. mps: 165 °C (Ref 9b), 165-175 °C (ref 10a).
- 12. Joshua, A. V.; Scott, J. R. Tetrahedron Lett. 1984, 25, 5725.
- 13. Ganem, B. Acc. Chem. Res. 1982, 15, 290.
- 14. Tice, C. M.; Ganem, B. J. Org. Chem. 1983, 48, 2106.
- 15. For 5: 1 H NMR (D₂O, 300 MHz) δ 8.49 (1H, s), 7.27 (1H, d, J = 1.1 Hz), 6.55 (1H, s), 3.13 (2H, t, J = 6.7 Hz), 2.82-2.99 (6H, m), 1.42-1.57 (4H, m); CMR (D₂O, dioxane, 75 MHz) δ 160.9, 126.5, 113.5, 105.5, 98.9, 47.3, 44.4, 38.4, 36.5, 25.8, 23.7, 23.0; FABMS (magic bullet) m/z 397 (M⁺).
- 16. Although patented (Ref 17), 7 has not been described in the primary literature: 1 H NMR (DMSO-d₆, 300 MHz, 87 °C) δ 2.95 (2H, t, J = 6.3 Hz), 2.73 (3H, br. s), 2.68 (2H, t, J = 6.7 Hz), 2.59 (2H, t, J = 6.8 Hz), 2.53 (2H, t, J = 6.6 Hz), 1.53 (2H, quintet, J = 6.7 Hz) 1.37-1.47 (13H, m); CMR (DMSO-d₆, 75 MHz) δ 155.6, 79.2, 59.7, 48.9, 46.9, 31.3, 28.3, 27.4, 26.6.
- 17. (a) Takeuchi, T.; Tomioshi, T.; Saino, T.; Takahashi, K.; Nakamura, T. 1989, Eur. Pat. Appl. EP 309,971; (b) Takeuchi, T; Saino, T.; Yoshida, M.; Takahashi, K.; Nakamura, T.; Umezawa, H. 1986, Eur. Pat. Appl. EP 241,797.
- 18. For 8: 1 H NMR (D₂O, 300 MHz) δ 6.61 (1H, s), 3.20 (2H, t, J = 6.5 Hz), 2.74-2.82 (6H, m), 1.70 (2H, quintet, J = 7.4 Hz) 1.48-1.50 (4H, m); CMR (D₂O, dioxane, 75 MHz) δ 162.3, 127.7, 114.0, 108.0, 98.1, 47.1, 45.2, 39.0, 36.2, 26.5, 24.6, 23.5; FABMS (magic bullet) m/z 397 (M⁺).

(Received in USA 8 June 1996; accepted 24 June 1996)